<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment protocols for bladder and urinary tract cancers
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment protocols for bladder and urinary tract cancers
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment protocols for bladder and urinary tract cancers
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tim Brenner, PharmD, BCOP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shrina Duggal, PharmD, BCOP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jim Natale, PharmD, BCOP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joaquim Bellmunt, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H14907009">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with bladder cancer in the neoadjuvant, adjuvant, or metastatic setting.
         <strong>
          This is
         </strong>
         <strong>
          not an exhaustive list
         </strong>
         ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with bladder cancer. Additional regimens may be added over time, particularly as treatment for bladder cancer evolves.
        </p>
        <p>
         This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with bladder cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2991.html" rel="external">
          "Neoadjuvant treatment options for muscle-invasive urothelial bladder cancer", section on 'Neoadjuvant chemotherapy'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2966.html" rel="external">
          "Adjuvant therapy for muscle-invasive urothelial carcinoma of the bladder"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3000.html" rel="external">
          "Treatment of metastatic urothelial carcinoma of the bladder and urinary tract"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy and immunotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy and immunotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.
        </p>
        <p class="headingAnchor" id="H14907233">
         <span class="h1">
          REGIMENS
         </span>
        </p>
        <p class="headingAnchor" id="H931770276">
         <span class="h2">
          Gemcitabine plus cisplatin (GC): 28-day cycle
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef53016" href="/z/d/graphic/53016.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p class="headingAnchor" id="H2593650258">
         <span class="h2">
          Gemcitabine plus cisplatin (GC): 21-day cycle
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef128074" href="/z/d/graphic/128074.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="headingAnchor" id="H3012710728">
         <span class="h2">
          Paclitaxel, gemcitabine, and cisplatin (PGC)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef140871" href="/z/d/graphic/140871.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="headingAnchor" id="H931770284">
         <span class="h2">
          Methotrexate plus vinblastine, doxorubicin, and cisplatin (MVAC)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef64950" href="/z/d/graphic/64950.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p class="headingAnchor" id="H2045253986">
         <span class="h2">
          Dose-dense methotrexate plus vinblastine, doxorubicin, and cisplatin (dose-dense MVAC)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef111814" href="/z/d/graphic/111814.html" rel="external">
          table 5
         </a>
         )
        </p>
        <p class="headingAnchor" id="H2026976485">
         <span class="h2">
          Nivolumab monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">
          table 6
         </a>
         )
        </p>
        <p class="headingAnchor" id="H1334486340">
         <span class="h2">
          Pembrolizumab monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 7
         </a>
         )
        </p>
        <p class="headingAnchor" id="H3087322537">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Scott M Wirth, PharmD, BCOP, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div id="topicVersionRevision">
        Topic 85676 Version 25.0
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
